

CME Information

Title: Laboratory Diagnosis and Therapeutic Monitoring in Hemophilia: Problems, Pitfalls, and Testing Pearls

Credits: 1.0 AMA/1.0 ANCC/1.0 ASCLS P.A.C.E®

Date: Thursday, January 19, 2017, 1:00PM–2:00PM EST

Jointly provided by Postgraduate Institute for Medicine, The Cardiovascular & Metabolic Health Foundation and Educational Concepts in Medicine

Target Audience

This activity has been designed to meet the educational needs of pathologists, pathology residents, laboratory directors, laboratory managers and administrators, chief medical technologists, hospital administrators, registered nurses, support staff, and other clinicians who are interested in the management of patients with hemophilia A or hemophilia B.

Educational Objectives

After completing this activity, the participant should be better able to:

- Review current issues, challenges, and problems related to the laboratory assessment of hemophilia A and B
- Discuss solutions – such as need to test both chromogenic and clot based assay to correctly diagnose non- severe hemophilia A and the need to accurately measure factor activity levels
- Provide an overview of the recombinant FVIII and FIX replacement products (currently in late-stage development or recently approved)
- Review some of the challenges facing clinical laboratories when monitoring some of these recombinant replacement products utilizing existing factor assays used in clinical laboratories.
- Discuss advantages and disadvantages of proposed solutions as well as existing current recommendations (i.e. MASAC)

Chairperson:

Dorothy M. Adcock M.D.

Medical Director

Colorado Coagulation, Laboratory Corporation of America® Holdings

Presenting Faculty:

Rajiv K Pruthi, M.B.B.S.

Associate Professor, Mayo Clinic College of Medicine

Co-Director, Special Coagulation Laboratory

Director Comprehensive Hemophilia Center, Mayo Clinic

Stefan Tiefenbacher, PhD

Vice President, Laboratory Corporation of America® Holdings

Technical Director of Coagulation

Colorado Coagulation, A LabCorp Specialty Testing Group

Program Agenda:

1:00PM-1:10PM ET: Introduction & Overview

1:10PM-1:25PM ET: What are and how do we solve the challenges and issues associated with the laboratory diagnosis of hemophilia A and B?

1:25PM- 1:40PM ET: What are and how do we solve the problems and overcome the pitfalls associated with monitoring factor replacement therapy?

1:40PM- 1:55PM ET: Case Review and Discussion

1:55PM-2:00PM ET: Questions and Answers

Physician Continuing Medical Education

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Postgraduate Institute for Medicine, Cardiovascular & Metabolic Health Foundation, and Educational Concepts in Medicine. The Postgraduate Institute for Medicine is accredited by the ACCME to provide continuing medical education for physicians.

The Postgraduate Institute for Medicine designates this live activity for a maximum of 1.0 *AMA PRA Category 1 Credit(s)*[™]. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Nursing Education

Postgraduate Institute for Medicine is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.

This educational activity for 1.0 contact hours is provided by Postgraduate Institute for Medicine.

P.A.C.E.[®] Continuing Education

Postgraduate Institute for Medicine has been approved as a provider of continuing education programs in the clinical laboratory sciences by the ASCLS P.A.C.E.[®] Program. This program is approved for up to 1.0 ASCLS P.A.C.E.[®] contact hour.

Disclosure of Conflicts of Interest

Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. The existence or absence of COI for everyone in a position to control content will be disclosed to participants prior to the start of each activity.

Fee Information

There is no fee for this educational activity.

A statement of credit will be issued immediately upon completing the evaluation on www.bloodcmecenter.org.

This activity is supported by an educational grant from Novo Nordisk.